Table 2.
Percentage of participants with rSBA titers≥1:8 and ≥1:128 and geometric mean titers against the serogroups MenA and MenC (mPPS cohort for immunogenicity).
| One dose group |
Two doses group |
|||||||
|---|---|---|---|---|---|---|---|---|
| N | titer≥1:8, %(95%CI) | titer≥1:128, %(95%CI) | GMT(95%CI) | N | titer≥1:8, %(95%CI) | titer≥1:128, %(95%CI) | GMT(95%CI) | |
| MenA | ||||||||
| Day 0 | 14 | 0.00 | 0.00 | 1.0 | 136 | 0.00 | 0.00 | 1.0 |
| Day 28 | 144 | 98.61 (95.07–99.83) | 90.97 (85.06–95.11) | 325.7 (268.6–394.8) | 135 | 100.00 (97.30–100.00) | 85.19 (78.05–90.71) | 311.2 (255.8–378.5) |
| Day 56 | – | – | – | – | 136 | 100.00 (97.32–100.00) | 86.76% (79.89–91.96) | 269.4 (228.8–317.2) |
| Month 12 | 129 | 71.32 (62.70–78.93) | 57.36 (48.36–66.03) | 53.9 (34.87–83.29) | 121 | 79.34 (71.03–86.16) | 57.85 (48.54–66.77) | 67.4 (45.1–100.6) |
| MenC | ||||||||
| Day 0 | 143 | 0.00 | 0.00 | 1.0 | 135 | 0.00 | 0.00 | 1.0 |
| Day28 | 143 | 97.20 (92.99–99.23) | 84.62 (77.64–90.10) | 227.9 (180.3–288.1) | 134 | 99.25 (95.91–99.98) | 81.34 (73.70–87.55) | 206.0 (166.1–255.6) |
| Day56 | – | – | – | – | 135 | 98.52 (94.75–99.82) | 81.48 (73.89–87.64) | 177.6 (147.2–214.3) |
| Month12 | 128 | 78.13 (69.96–84.95) | 29.69 (21.94–38.40) | 29.2 (19.8–42.9) | 120 | 80.83 (72.64–87.44) | 26.67 (19.01–35.51) | 26.14 (18.7–36.6) |
One dose group, participants who received 1 dose at day 0; two doses group, participants who received 2 dose at day 0 and 28; N, number of participants with available results; day 0, the day of first dose; day 28, 28 days post the first dose; day 56, 56 days post the first dose; month 12, 12 month post the first dose; 95% CI, 95% confidence interval.